Stereotactic Radioablation for Ventricular Tachycardia

(START-VT Trial)

This trial tests a new treatment for individuals with ventricular tachycardia (VT), a serious heart rhythm issue often associated with scarred heart tissue. The treatment, Stereotactic Arrhythmia Radioablation (STAR), uses precise radiation to target and repair the scarred areas causing the abnormal rhythm. Researchers aim to determine if STAR can safely and effectively prevent VT episodes without the side effects of current treatments. Individuals with a history of VT and heart damage visible on scans, especially those still experiencing symptoms or shocks from their defibrillator, might be suitable candidates for this study. Participants will undergo monitoring for a year to evaluate the treatment's effectiveness and check for any side effects. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could lead to new treatment options for VT.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that Stereotactic Arrhythmia Radioablation (STAR) is generally safe and well-tolerated for people with ventricular tachycardia (VT), a type of fast heart rhythm. Studies have found that STAR can significantly reduce episodes of VT, with one study noting an 87% decrease in these episodes. Importantly, there was no significant drop in heart or lung function, indicating the treatment does not harm these areas.

Another study found that STAR is safe in the short term, with no major heart-related side effects. STAR offers similar results to catheter ablation, a more traditional treatment, but has the advantage of being non-invasive, meaning it doesn't involve surgery and carries less risk.

Unlike traditional treatments for ventricular tachycardia that often involve catheter ablation or medication, stereotactic arrhythmia radioablation (STAR) offers a non-invasive alternative by using targeted radiotherapy. This method, similar to treatments used in cancer therapy, precisely delivers radiation to the area of the heart causing the arrhythmia. Researchers are excited about STAR because it has the potential to reduce recovery time and minimize the risks associated with invasive procedures, all while maintaining high precision in targeting the problematic heart tissue. This innovative approach could eventually transform how ventricular tachycardia is treated, providing a safer and more efficient option for patients.

Studies have shown promising results for Stereotactic Arrhythmia Radioablation (STAR) in treating ventricular tachycardia (VT), a condition characterized by an excessively fast heartbeat. Previous research demonstrated that STAR reduced VT episodes by about 81.5% and shocks from an implantable heart device by about 84.7%. Another study found a 99.9% reduction in VT episodes just six weeks after treatment. STAR is a non-invasive treatment targeting the heart's scar tissue responsible for the abnormal rhythm. While some studies suggest it may not always be effective long-term for everyone, many patients have experienced significant improvements. This trial will evaluate STAR as a promising option for those dealing with VT.⁴⁶⁷⁸⁹